Deep Learning on Amyloid Positons Emission Tomography
DEEPAMY
Impact of Deep Learning-Based Noise Reduction Algorithm on Visual Analysis and Centiloid Quantification in Reduced-Dose and, or Time Acquisition Amyloid PET Imaging
1 other identifier
observational
40
1 country
3
Brief Summary
Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of \[18F\]flutemetamol.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2026
Shorter than P25 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 24, 2025
CompletedFirst Posted
Study publicly available on registry
December 30, 2025
CompletedStudy Start
First participant enrolled
May 6, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 20, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 30, 2027
June 25, 2026
June 1, 2026
7 months
November 24, 2025
June 23, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluate the impact of a deep-learning noise reduction algorithm on visual analysis and centiloid quantification when simulating reduced injected doses of 18F-flutemetamol.
Visual analysis of the cerebral \[¹⁸F\]flutemetamol PET images will be performed by two nuclear medicine specialists in a blinded manner, with a third reader acting as an arbitrator in case of disagreement, according to routine diagnostic criteria.
Day one
Eligibility Criteria
Patients with objective cognitive impairment, referred to our department for a cerebral \[¹⁸F\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025, will be included
You may qualify if:
- Patients with objective cognitive impairment,
- Referred to our department for a cerebral \[¹⁸F\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,
You may not qualify if:
- Patient have objected to the use of their data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
CHRU NANCY Brabois, nuclear medicine department
Vandœuvre-lès-Nancy, 54511, France
Nancy's hospital
Vandœuvre-lès-Nancy, 54511, France
Nuclear medicine department CHRU de NANCY Brabois
Vandœuvre-lès-Nancy, 54511, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Principal Investigator
CHRU of NANCY
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 24, 2025
First Posted
December 30, 2025
Study Start
May 6, 2026
Primary Completion (Estimated)
November 20, 2026
Study Completion (Estimated)
January 30, 2027
Last Updated
June 25, 2026
Record last verified: 2026-06